Skip to Main Content

Paper Details

MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial.
Int J Cancer
9
2021
-, -STP27, CCNU, CeTeG, DNA methylation arrays, MGMT, MGMT promoter, NOA, NOA-09, PSQ, Patients, STP27, TMZ, glioblastoma, patients, qMSP, tumors
Author NameAffiliation
Theophilos TzaridisDivision of Clinical Neurooncology, University of Bonn
Theophilos TzaridisUniversity of Bonn
Hartmut VatterUniversity of Bonn
Martin GlasDivision of Clinical Neurooncology, University of Bonn
Martin GlasDivision of Clinical Neurooncology, Department of Neurology and West German Cancer Center (WTZ), University Hospital Essen, University Duisburg-Essen
Torsten PietschInstitute of Neuropathology and DGNN Brain Tumor Reference Center, University of Bonn
Guido ReifenbergerInstitute of Neuropathology and DGNN Brain Tumor Reference Center, Heinrich Heine University and German Cancer Consortium (DKTK)
  • 1 - 7

Datasets